HC Wainwright & Co. Maintains Buy on TriSalus Life Sciences, Raises Price Target to $12

Benzinga · 3d ago
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and raises the price target from $11 to $12.